Scarica l'app Stockscreener
7.37
0.27%
0.02
Precedente Chiudi:
$7.35
Aprire:
$7.38
Volume 24 ore:
1.11M
Relative Volume:
0.63
Capitalizzazione di mercato:
$455.11M
Reddito:
$2.00M
Utile/perdita netta:
$-43.51M
Rapporto P/E:
-5.4939
EPS:
-1.3415
Flusso di cassa netto:
$-39.73M
1 W Prestazione:
-3.15%
1M Prestazione:
+13.38%
6M Prestazione:
+18.68%
1 anno Prestazione:
-25.63%
Intervallo 1D:
$6.9584
$7.59
Intervallo di 1 settimana:
$6.9584
$7.92
Portata 52W:
$4.50
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.37 | 455.11M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-03 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-08-11 | Iniziato | Wedbush | Outperform |
| 2025-08-07 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-24 | Iniziato | Canaccord Genuity | Buy |
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences(SGMT) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – SWB:0O2 - TradingView
Sagimet Biosciences (SGMT) Financials 2026Income Statement and Balance Sheet - MarketBeat
Sagimet Biosciences to join Russell 3000 and Russell 2000 as part of 2026 index reconstitution - Traders Union
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Sagimet Therapeutics: Buy Rating Affirmed as Clinically De‑Risked FASN Franchise Advances; Price Target Raised to $31 - TipRanks
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com
Sagimet Biosciences Added to Russell Indexes - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Index - marketscreener.com
Sagimet Biosciences added to Russell 2000 and 3000 indexes By Investing.com - Investing.com South Africa
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Value Benchmark - marketscreener.com
Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT) - TradingView
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Sagimet Biosciences (SGMT) Joins Russell 3000 and Russell 2000 I - GuruFocus
Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Index - marketscreener.com
Price to earnings forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Value Benchmark - marketscreener.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Enterprise value to EBITDA forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Enterprise value to EBITDA forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Price to book forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to revenue forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Sagimet Biosciences Inc (SGMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0O2 Forecast — Price Target — Prediction for 2027 - TradingView
SGMT Forecast — Price Target — Prediction for 2027 - TradingView
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Sagimet Biosciences Inc (SGMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Eastern Progress
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sagimet Biosciences (SGMT) Edges Higher as Biotech Sector Gains MomentumZigzag Correction - dars.gov.et
SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive ReactionDividend Growth Analysis - dars.gov.et
SGMT News | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged - TipRanks
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Biosciences Inc (SGMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sagimet Biosciences Inc (SGMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sagimet Biosciences Inc (SGMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sagimet Biosciences Inc (SGMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sagimet Biosciences Inc (SGMT) Institutional Confidence - TradingKey
Sagimet Biosciences Inc (SGMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sagimet Biosciences Inc Azioni (SGMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):